KEY POINTS
- Merck shares fell 3.9% to $112.47 on Tuesday after the Phase 3 LITESPARK-012 trial for advanced kidney cancer failed to meet its primary endpoints for progression-free survival and overall survival.
- Gardasil demand in China remains weak, with Merck extending its shipment pause to the region, pressuring confidence in near-term vaccine revenue growth.
- The next catalyst is second-quarter guidance and any update on the Gardasil China resumption timeline, with the stock now testing the $110 support level that held during the March sell-off.
Merck shares fell 3.9% to $112.47 on Tuesday, making the pharmaceutical giant the worst performer on the Dow as a failed late-stage cancer trial collided with persistent concerns about the company's vaccine franchise and soft 2026 earnings outlook.
The primary catalyst was the LITESPARK-012 trial failure. The Phase 3 study, conducted in collaboration with Eisai, evaluated combination regimens for first-line treatment of advanced renal cell carcinoma. At a pre-specified interim analysis, the combination did not meet its dual primary endpoints of progression-free survival and overall survival. The failure removes a pipeline asset that had been valued at between $1.5 billion and $2.5 billion in peak annual sales by several sell-side models.
The Pipeline Math Gets Harder
Merck's investment thesis has long centered on Keytruda, the blockbuster cancer immunotherapy that generates more than $25 billion in annual revenue. But Keytruda's core U.S. patents begin expiring in 2028, creating a revenue cliff that management has been racing to offset through combination therapies and new indications. LITESPARK-012 was one of several trials designed to extend Keytruda's commercial life by pairing it with next-generation agents.
The failure narrows the pipeline funnel at a moment when investors are already skeptical about Merck's ability to replace Keytruda revenue. The company has a dozen combination studies in late-stage development, but each failure reduces the probability-weighted value of the overall portfolio and raises the pressure on remaining assets to deliver.
Analysts at several major firms maintained their ratings but lowered price targets by $5 to $10, citing the reduced optionality. The consensus 12-month target drifted to approximately $130 from $140 prior to the announcement. The stock is now trading at roughly 10 times forward earnings, a discount to its five-year average of 13 times and a level that historically attracts value-oriented institutional buyers.
Gardasil's China Problem
The trial failure landed on a stock already weakened by concerns about Gardasil demand in China. Merck extended its pause on HPV vaccine shipments to the Chinese market amid continued weakness in orders, a headwind that has persisted for three consecutive quarters and shows no clear signs of resolution.
Gardasil was a $9 billion annual revenue product at its peak, with China representing a significant and growing share. The shipment pause reflects both a domestic inventory overhang and increased competition from locally manufactured alternatives. Merck has not provided a specific timeline for resumption, and the uncertainty has become a consistent drag on the stock.
The vaccine weakness compounds the pipeline concern because Gardasil was supposed to be a durable revenue base that provided cash flow stability while the Keytruda transition played out. With both pillars under pressure simultaneously — the pipeline from the trial failure and vaccines from the China pause — Merck's near-term earnings trajectory looks weaker than it did even a week ago.
Where Support Sits
The 3.9% decline took MRK to $112.47, testing the $110 level that served as support during the March sell-off. That level held twice in March on intraday dips, attracting buyers who viewed the stock's dividend yield — now above 3.5% — as compelling relative to the 10-year Treasury near 4.2%.
Volume on Tuesday was elevated but not extreme, suggesting the selling was institutional rebalancing rather than panic. The options market showed increased activity in May $110 puts, indicating some hedging of further downside risk, but call volume at the $120 strike also picked up, pointing to contrarian interest.
The next meaningful catalyst is management's Q2 commentary, expected in late July, which should include an update on the Gardasil China resumption timeline and the remaining LITESPARK program readouts. If $110 holds through the current cycle of macro uncertainty and the Gardasil pause shows any signs of lifting, the stock's valuation at 10 times earnings starts to look like a floor. A break below $110, conversely, opens the door to $100, a level the stock has not seen since early 2024 and one that would imply the market is pricing permanent impairment to the pipeline thesis.
